Opendata, web and dolomites

PeptiCrad SIGNED

Personalized oncolytic vaccines for cancer immunotherapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "PeptiCrad" data sheet

The following table provides information about the project.

Coordinator
HELSINGIN YLIOPISTO 

Organization address
address: YLIOPISTONKATU 3
city: HELSINGIN YLIOPISTO
postcode: 14
website: www.helsinki.fi

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Finland [FI]
 Project website https://www.helsinki.fi/en/researchgroups/immunovirotherapy-lab/research
 Total cost 1˙975˙705 €
 EC max contribution 1˙975˙705 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2015-CoG
 Funding Scheme ERC-COG
 Starting year 2016
 Duration (year-month-day) from 2016-07-01   to  2021-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HELSINGIN YLIOPISTO FI (HELSINGIN YLIOPISTO) coordinator 1˙975˙705.00

Map

 Project objective

This grant application proposes to develop a novel, customizable and personalized anti-cancer vaccine: peptide-coated conditionally replicating adenovirus (PeptiCrad). Anti-cancer vaccines represent a promising approach for cancer treatment because they elicit durable and specific immune response that destroys primary tumors and distant metastases. Oncolytic viruses (OVs) are of significant interest because in addition to cytolysis they stimulate anti-tumor immune responses, thereby functioning as anti-tumor vaccines. However, their efficacy among cancer patients has been modest. One reason for this shortcoming is that the immune responses generated by virus infection primarily target the virus rather than the tumor. In addition, tumors differ across patients. Specific and personalized approaches (rather than generic virus infection strategies) are required to optimize therapy. To this end we propose to develop a novel vaccine platform that combines the strengths of OVs with the specificity of vaccines. Our technology is called PeptiCrad. PeptiCrad is a virus “dressed as a tumor”. It directly kills cancer cells (i.e., oncolytic viruses) and expresses immunomodulatory molecules (i.e., cytokines or the immune checkpoint inhibitors anti-CTLA4 or anti-PDL1); most importantly, it diverts immunity toward the tumor (i.e., the capsid becomes covered with MHC-I-restricted tumor-specific peptides). The method that we have developed to cover the virus with tumor peptides is novel and exceeds current state-of-the-art. Importantly, it is fast and does not require genetic or chemical manipulation of the virus; this feature has a significant impact on the translational capability of the project. Our preliminary results show great potential but significant questions regarding the development and the personalization of PeptiCrad remain to be studied. In this grant I propose two lines of research, one focused on the development and the other one on the personalization of PeptiCrad.

 Publications

year authors and title journal last update
List of publications.
2020 Siri Tähtinen, Sara Feola, Cristian Capasso, Netta Laustio, Christianne Groeneveldt, Erkko O Ylösmäki, Leena Ylösmäki, Beatriz Martins, Manlio Fusciello, Marta Medeot, Maria Tagliamonte, Jacopo Chiaro, Firas Hamdan, Karita Peltonen, Tuuli Ranki, Luigi Buonaguro, Vincenzo Cerullo
Exploiting pre-existing immunity to enhance oncolytic cancer immunotherapy
published pages: canres.2062.2019, ISSN: 0008-5472, DOI: 10.1158/0008-5472.can-19-2062
Cancer Research 2020-03-24
2015 Cristian Capasso, Mari Hirvinen, Mariangela Garofalo, Dmitrii Romaniuk, Lukasz Kuryk, Teea Sarvela, Andrea Vitale, Maxim Antopolsky, Aniket Magarkar, Tapani Viitala, Teemu Suutari, Alex Bunker, Marjo Yliperttula, Arto Urtti, Vincenzo Cerullo
Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma
published pages: e1105429, ISSN: 2162-402X, DOI: 10.1080/2162402X.2015.1105429
OncoImmunology 5/4 2020-02-05
2019 Alessandra Lopes, Sara Feola, Sophie Ligot, Manlio Fusciello, Gaëlle Vandermeulen, Véronique Préat, Vincenzo Cerullo
Oncolytic adenovirus drives specific immune response generated by a poly-epitope pDNA vaccine encoding melanoma neoantigens into the tumor site
published pages: , ISSN: 2051-1426, DOI: 10.1186/s40425-019-0644-7
Journal for ImmunoTherapy of Cancer 7/1 2020-02-05
2019 Manlio Fusciello, Flavia Fontana, Siri Tähtinen, Cristian Capasso, Sara Feola, Beatriz Martins, Jacopo Chiaro, Karita Peltonen, Leena Ylösmäki, Erkko Ylösmäki, Firas Hamdan, Otto K. Kari, Joseph Ndika, Harri Alenius, Arto Urtti, Jouni T. Hirvonen, Hélder A. Santos, Vincenzo Cerullo
Artificially cloaked viral nanovaccine for cancer immunotherapy
published pages: , ISSN: 2041-1723, DOI: 10.1038/s41467-019-13744-8
Nature Communications 10/1 2020-02-04
2018 S. Feola, C. Capasso, M. Fusciello, B. Martins, S. Tähtinen, M. Medeot, S. Carpi, F. Frascaro, E. Ylosmäki, K. Peltonen, L. Pastore, V. Cerullo
Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors
published pages: e1457596, ISSN: 2162-402X, DOI: 10.1080/2162402x.2018.1457596
OncoImmunology 2019-06-18
2017 Cristian Capasso, Aniket Magarkar, Victor Cervera-Carrascon, Manlio Fusciello, Sara Feola, Martin Muller, Mariangela Garofalo, Lukasz Kuryk, Siri Tähtinen, Lucio Pastore, Alex Bunker, Vincenzo Cerullo
A novel in silico framework to improve MHC-I epitopes and break the tolerance to melanoma
published pages: e1319028, ISSN: 2162-402X, DOI: 10.1080/2162402X.2017.1319028
OncoImmunology 6/9 2019-06-18
2018 S. Feola, C. Capasso, M. Fusciello, B. Martins, S. Tähtinen, M. Medeot, S. Carpi, F. Frascaro, E. Ylosmäki, K. Peltonen, L. Pastore, V. Cerullo
Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors
published pages: e1457596, ISSN: 2162-402X, DOI: 10.1080/2162402x.2018.1457596
OncoImmunology 2019-05-25

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PEPTICRAD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PEPTICRAD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

SUExp (2018)

Strategic Uncertainty: An Experimental Investigation

Read More  

InsideChromatin (2019)

Towards Realistic Modelling of Nucleosome Organization Inside Functional Chromatin Domains

Read More  

NanoMechShape (2019)

Molecular control of actin network architecture and mechanics during cell shape changes

Read More